Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/5568
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kocabaş, Umut | - |
dc.contributor.author | Ergin, Işıl | - |
dc.contributor.author | Yavuz, Veysel | - |
dc.contributor.author | Altın, Cihan | - |
dc.contributor.author | Kaplan, Mehmet | - |
dc.contributor.author | Oztekin, Guelsuem Meral Yilmaz | - |
dc.contributor.author | Dogdus, Mustafa | - |
dc.date.accessioned | 2024-10-25T15:17:53Z | - |
dc.date.available | 2024-10-25T15:17:53Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 2055-5822 | - |
dc.identifier.uri | https://doi.org/10.1002/ehf2.15049 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14365/5568 | - |
dc.description.abstract | Aims: We aimed to determine the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting. Methods: Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023. Results: The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19-101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06-3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27-9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16-6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72-13.20; P < 0.001), the use of angiotensin receptor-neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39-7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49-2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18-2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30-2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45-0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37-0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48-0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49-0.91; P = 0.010) were independently associated with the non-use of SGLT2is. Conclusions: The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease. | en_US |
dc.description.sponsorship | We would like to thank Prof. Dr. Seckin Pehlivanolu for his critical review of this study. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley Periodicals, Inc | en_US |
dc.relation.ispartof | Esc heart failure | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | guideline | en_US |
dc.subject | heart failure | en_US |
dc.subject | sodium-glucose cotransporter 2 inhibitors | en_US |
dc.subject | Esc Guidelines | en_US |
dc.subject | Outcomes | en_US |
dc.title | Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study | en_US |
dc.type | Article | en_US |
dc.type | Article; Early Access | en_US |
dc.identifier.doi | 10.1002/ehf2.15049 | - |
dc.identifier.pmid | 39340234 | en_US |
dc.identifier.scopus | 2-s2.0-85205077364 | en_US |
dc.department | İzmir Ekonomi Üniversitesi | en_US |
dc.authorid | Cakan, Fahri/0000-0002-5427-3480 | - |
dc.authorscopusid | 57211015002 | - |
dc.authorscopusid | 25951372300 | - |
dc.authorscopusid | 55457354700 | - |
dc.authorscopusid | 23979295100 | - |
dc.authorscopusid | 56824971000 | - |
dc.authorscopusid | 57207828905 | - |
dc.authorscopusid | 57204894031 | - |
dc.identifier.wos | WOS:001321727100001 | en_US |
dc.institutionauthor | … | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.openairetype | Article; Early Access | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | 09.02. Internal Sciences | - |
crisitem.author.dept | 09.02. Internal Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.